NewSquare Capital LLC Has $4.19 Million Position in Pfizer Inc. (NYSE:PFE)

NewSquare Capital LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 3.0% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 147,446 shares of the biopharmaceutical company’s stock after buying an additional 4,354 shares during the quarter. NewSquare Capital LLC’s holdings in Pfizer were worth $4,190,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Briaud Financial Planning Inc acquired a new position in shares of Pfizer during the third quarter valued at $30,000. Mizuho Securities Co. Ltd. bought a new position in shares of Pfizer in the 3rd quarter valued at about $34,000. VisionPoint Advisory Group LLC grew its position in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer in the fourth quarter valued at approximately $36,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Down 0.2 %

Pfizer stock traded down $0.05 during mid-day trading on Wednesday, reaching $26.27. The company’s stock had a trading volume of 12,366,906 shares, compared to its average volume of 41,730,246. The business’s 50 day simple moving average is $27.07 and its 200 day simple moving average is $28.52. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The company has a market capitalization of $148.75 billion, a price-to-earnings ratio of 72.72, a price-to-earnings-growth ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the business earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. As a group, research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have commented on the stock. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.